These are the catalysts shareholders can look forward to over the next 18 months. Timelines are based on current guidance and payments anticipated in 2023 are obviously dependent on the FDA approving trofinetide in Rett syndrome.
By end July 22 - Acadia to submit NDA for trofinetide in Rett syndrome
- Commencement of 3 x Phase 2 trials of NNZ-2591
By end Sep. 22 - FDA acceptance of NDA - NEU to receive ~A$14.5m from Acadia
By end Dec. 22 - Commencement of 4th Phase 2 trial of NNZ-2591
- Licence deal/s for trofinetide for ex-North America territories
By end Mar. 23 - FDA decision on marketing approval for trofinetide in Rett syndrome
- NEU to receive from Acadia ~ A$58m on approval and launch in U.S.
By end Dec. 23 - Results of Phase 2 trials in NNZ-2591
- NEU to receive ~ A$48m from sale of Priority Review Voucher
- First royalties (10%+) from U.S. sales of trofinetide
Share Price, page-1540
-
- There are more pages in this discussion • 9,308 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.49 |
Change
0.630(3.17%) |
Mkt cap ! $2.626B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $4.400M | 216.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 59 | $20.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.50 | 1616 | 3 |
View Market Depth
| Last trade - 14.24pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |